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Atrial fibrillation (AF) is a common cardiac/heart disease 
that increases a person’s risk of death, making early 
identification significant in overall disease management. 
Throughout my time in pharmacy school, I [Brian] have 
developed an interest in cardiology and research. During 
my last year of pharmacy school, I spent eight weeks at 
St. Bartholomew’s Hospital in London, one of the largest 
cardiac centers in Europe, on an experiential training 
experience. While there, I had the opportunity to study 
specifics about many cardiac illnesses, with a focus on 
atrial fibrillation, and provide education to patients living 
with this disease. In addition to working with patients 
and expanding my knowledge, I participated in an excit-
ing research project that allowed me to connect with 
the general population and share my knowledge about 
arrhythmias, which is something I would like to continue 
to do after graduation. 
Our research project aimed to identify the role phar-
macists could play in early detection of arrhythmias, 
particularly atrial fibrillation, and increase the popula-
tion’s awareness and understanding of this illness. For our 
project, a pharmacist or student pharmacist was partnered 
with nursing staff to provide opportunities for heart rate 
and rhythm monitoring as well as individualized educa-
tion to help ensure interested patients were more aware 
of the risks, signs, and symptoms of atrial fibrillation 
going forward. When patients met with the team, they had 
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shortness of breath, tiredness, chest pain, dizziness, and 
blood clots. The blood clots are often a cause of strokes 
(Miller 2005; Lin 1996). Patients living with AF are at a 
fivefold increase of having a stroke and comprise about 
one third of all ischemic stroke patients (Freedman 2016; 
Wolf 1991; Kannel 2008). Aside from the increased 
risk of stroke, AF also triples a patient’s risk of heart 
 failure (Stewart 2002) and presents patients with nearly a 
twofold- increased risk of mortality (Benjamin 1998). All 
of these illnesses can decrease a person’s longevity and 
increase their overall health care costs.
Globally, atrial fibrillation is the most commonly iden-
tified heart rhythm disturbance and its prevalence is 
predicted to rise in the coming years (Morillo 2017; 
Chugh 2014). A systematic review published in 2010 
analyzed 184 population- based studies published from 
1980–2010 from the 2010 Global Burden of Diseases, 
Injuries, and Risk Factors Study. This analysis showed 
that in 2010, worldwide prevalence of AF was estimated 
to be at 33.5 million individuals, with males (20.9 mil-
lion) being more affected than females (12.6 million) 
(Chugh 2014). This study also revealed the median 
percentage change of AF has increased by roughly 5% 
globally from 1990 to 2010, with the prevalence increas-
ing from 452 to 474 patients per 100,000 (Chugh 2014).
While the global prevalence of AF appears to be grow-
ing, it is currently more common in higher- income and 
more developed countries (Morillo 2017). The United 
States has the greatest prevalence of AF with approxi-
mately 2% of the population under the age of 65 years 
old and 9% of the population above the age of 65 
expected to be affected (Centers for Disease Control and 
Prevention 2003). By 2030, as the population continues 
to age, the Centers for Disease Control and Prevention 
expect this number to increase to 19.6% of people over 
the age of 65 years old (Centers for Disease Control and 
Prevention 2003; Morillo 2017; January 2014). While the 
prevalence of AF in the United Kingdom is lower than in 
the United States, the U.K. does have the highest per-
centage of death contributed to AF, with just over 0.9% 
of deaths being associated with AF and atrial flutter in 
2010 (Morillo 2017).
To combat the growing prevalence and associated 
morbidity and mortality of AF, organizations such as the 
Atrial Fibrillation Association, the Arrhythmia Alliance, 
and the International Pharmacists for  Anticoagulation 
Care Taskforce have made coordinated efforts to identify 
patients at high risk for AF and refer them for appropri-
ate treatment. One method being trialed is the use of 
mobile, single- lead electrocardiogram (ECG) tools to 
their heart rhythms assessed using the AliveCor Kardia 
single- lead electrocardiogram (ECG) system. This new 
technology allows patients to place their fingers on a small 
strip that is able to accurately assess a person’s heart rate 
and rhythm to identify any irregularities/arrhythmias. 
Participants were also provided education about atrial 
fibrillation in hopes of preventing significant  morbidity 
and mortality, raising awareness about this particular 
disease and connecting patients with care. Part of this edu-
cation included us showing the patients how to manually 
take an accurate pulse reading, and how to differentiate 
between a normal and irregular rate and rhythm. By teach-
ing the patients these skills, they now know what to look 
for, how to monitor their own pulse, and when to seek 
help in the event they, or someone they know, experience 
symptoms of atrial fibrillation.
INTRODUCTION
Pharmacists are health professionals who have wide-
spread access to the general population in community 
and ambulatory care settings as well as within hospitals. 
Recent data from Forbes highlights that pharmacists 
remain one of the most trusted and ethical professions 
behind nurses and physicians (McCarthy 2019). Given 
their easy accessibility, connection to the community, 
and understanding of medications, they are a trusted 
resource for many people. Pharmacists are able to 
provide education on a variety of disease states includ-
ing cardiac conditions such as atrial fibrillation (AF), 
an irregular heart rhythm, as well as any related medi-
cations. They are also a medication resource for other 
health care professionals such as physicians, physician 
assistants, and nurses and are often consulted to assist 
in medication selection and monitoring. Pharmacists 
are well placed to aid in identifying patients at high risk 
for certain diseases, given the right technology, and are 
able to provide appropriate referrals for needed medi-
cal management. They are especially well placed to be 
able to identify patients with asymptomatic diseases who 
wouldn’t have reason to suspect such a serious health 
issue. Uncovering these conditions early could help 
patients by preventing a potentially debilitating or fatal 
consequence of their disease.
One disease state that pharmacists can aid in detecting 
and managing is atrial fibrillation (AF). AF is a cardiac 
disease that occurs when the atria of the heart receive 
disordered electrical impulses, which in turn cause the 
heart to beat irregularly and pump blood less efficiently 
(January 2014; National Institute for Health and Care 
Excellence [NICE] 2014). This irregular heartbeat 
can cause various symptoms including palpitations, 
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screenings with support from the Arrhythmia Alliance, 
who provided educational material to be distributed to 
patients.
Upon screening acceptance and before screening, patients 
completed an informed consent form. Basic demographic 
information recorded included age and gender as well 
as identification of common AF symptoms including 
palpitations, shortness of breath, tiredness, chest pain, 
dizziness, and irregular pulse. Medical history such as 
high blood pressure, heart muscle disease, diabetes, 
peripheral artery disease, stroke, transient ischemic 
attack, clot in the body (excluding lungs), heart attack, 
and medication history with a focus on antiplatelet and 
anticoagulation drugs were documented. Patients were 
educated on the basic disease state information includ-
ing presenting symptoms and how to detect their own 
pulse and heart rate properly. During the screening, each 
patient’s heart rate and pulse were recorded after manual 
assessment.
Patients were then assessed using the Kardia system to 
screen for AF and other potential arrhythmias. Patients 
receiving a “Normal” heart rhythm and an acceptable 
heart rate were classified as not currently being sus-
pected of AF or further arrhythmia and were permitted to 
screen patients before they encounter an adverse event 
from AF. The AliveCor Kardia (Kardia) system (Figure 
1) is one such tool with high rates of accuracy that is also 
easy to use, less invasive than traditional ECG monitors, 
and readily available (Koshy 2018). The Kardia system 
reads heart rate and rhythm from a person’s fingertips 
and sends real- time data directly to a smartphone run-
ning the partnered Kardia software application. After 
30 seconds, the Kardia program will interpret the reading 
and provide an evaluation of “Normal,” “Possible Atrial 
Fibrillation” (indicating a rhythm consistent with AF) 
or “Unclassified,” (indicating the potential presence of a 
non- AF arrhythmia). 
In this study, we examined the role pharmacy team 
members could have using such a system to screen for 
high- risk patients outside of the hospital. Since many 
pharmacists interact with patients in a community or 
ambulatory care, having the ability to accurately screen 
for AF allows for increased patient access and poten-
tially quicker connection to needed medical care. 
METHODOLOGY
This multicenter AF screening study was conducted 
in various locations in Greater London, England. Data 
was collected in 2017–2018 during heart awareness 
and “Know Your Pulse” awareness campaigns at Saint 
Bartholomew’s Hospital, Moorfield Hospital, Redbridge 
Hospital, and SCCP Hospital (Figure 2). These cam-
paigns consisted of weeklong pulse screenings at stations 
positioned in the common areas of these facilities and 
opened to all interested individuals over the age of 18 
regardless of their medical history. Pharmacists, cardi-
ology nurses, and pharmacy learners conducted these 
Figure 1. AliveCor Kardia system in use.
Figure 2. Monica and Brian taking part in an AF screening.
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disease, and diabetes, which were reported in 29.5%, 
15.0%, and 13.1% of the population, respectively.
Figure 4 highlights the results from the Kardia screen-
ings. Of the 1,144 analyzed profiles, 37 patients (3.2%) 
were identified as potentially or knowingly being in AF. 
Of these, 25 (67.6%) were ≥65 years old at the time of 
screening, and 23 (62.2%) were previously unaware of 
their likely AF status. An additional 62 patients (5.4%) 
were screened and found to potentially have an irregu-
lar, but non- AF, heart rhythm. In total, 99 patients were 
identified as having a potential arrhythmia and referred 
to further care as a direct result of pharmacist and phar-
macy learner led ECG screenings. The remaining 1,045 
patients (91.4%) were shown to have a “Normal” heart 
rhythm interpretation upon screening.
DISCUSSION
The 99 patients identified with an abnormal heart rate 
represent approximately 3.2% of the total population 
screened. This result is higher than the 1.6% of the 
population of England as predicted by NICE in 2013 
(National Institute for Health and Care Excellence 2013). 
The variance could be potentially explained by the high 
percentage of patients taken from an urban  environment, 
where rates of AF tend to be higher. In addition, a screen-
ing site located in one of the largest cardiac centers in 
Europe could have led to a population more skewed 
towards having cardiovascular conditions. Furthermore, 
patients with preexisting heart conditions at this facility 
accompanied by family members with similar genetic 
risks may be more likely to be visiting the hospital where 
a majority of the screenings were held.
COMMUNITY IMPACT
This service- learning project was originally designed to 
help assess the role pharmacy team members could have 
in early detection of AF, but by the end of this project 
much more was accomplished. By this study’s conclusion 
leave without any need for acute follow up. Patients that 
displayed an “Unclassified” or “Possible Atrial Fibrilla-
tion” heart rhythm were reassessed using the Kardia. If 
the irregularity was duplicated and the patient remained 
as “Unclassified” or “Possible Atrial Fibrillation,” 
the ECGs were reviewed in detail and the patient was 
referred for a full 12- lead ECG workup via their primary 
care physician or current hospital site if available. Upon 
referral, if AF was confirmed, anticoagulation therapy 
was recommended by the pharmacy team in accordance 
with national guidelines. 
The primary endpoint for this study was to assess the role 
pharmacy team members could have in providing early 
detection of AF and subsequent referral to care using the 
Kardia single- lead ECG system in a nonhospital setting. 
This was assessed by the number of patients identified 
as having potentially abnormal ECGs that were screened 
and referred to further care using the Kardia system. 
St. Bartholomew’s Health Clinical Effectiveness Unit 
granted ethical approval for this study.
RESULTS
This study enrolled 1,298 patients, of which 154 were 
excluded due to incomplete data collection, leaving 
1,144 patients available for analysis. Despite exclusions, 
all 1,298 patients did receive one- on- one arrhythmia 
counseling and education from a pharmacist, pharmacy 
learner, or cardiac nurse. Figure 3 highlights the num-
ber of patients screened at each location. The 1,144 
patients with complete data had a mean age of 55 years, 
a median age of 57 years, and a range of 18–101 years 
old. Approximately one third of this population was con-
sidered elderly, with 371 (32.4%) being ≥65 years old. 
When assessed by gender, more males were screened 
(639) compared to females (505), with men making 
up 55.9% of the patient cohort. The most commonly 
reported risk factors were hypertension, peripheral artery 
Figure 3. Atrial fibrillation screenings by location.
Figure 4. AliveCor Kardia screening results.
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and document a patient’s official diagnosis following 
their 12- lead screening would be valuable information. 
As participant names were not recorded and tied to their 
screening results during this project for anonymity, this 
information was hard to collect retrospectively. Future 
versions of this service- learning project will likely see 
a higher level of follow- up for patients with potential 
arrhythmias, in order to ensure they receive proper 
treatment and to better quantify the results of such a 
screening program. Another target for future screening 
events would be to have the ability to offer immedi-
ate follow- up with a full, 12- lead ECG at all screening 
locations. While the majority of participants in this study 
were assessed at St. Bartholomew’s where this service 
was readily available, being able to offer this conve-
nience to all patients deemed to be at higher risk could 
help increase the rate of follow- up care in any upcoming 
screening events.
Another challenge was presented by the fact that 
multiple parts of the screening and accompanying 
questionnaire were dependent on patient- reported 
responses. While interviewing patients, it was easy to 
see the varying amount of knowledge some participants 
held regarding their own health, which could impact the 
quality of the data received from the patient interviews. 
This was especially apparent for questions regarding less 
common risk factors or comorbidities such as peripheral 
artery disease or venous thromboembolisms. This vari-
able would be difficult to eliminate in such a nonclinical 
setting, but there is potential for screening services simi-
lar to this one to be carried out in lower acuity medical 
settings such as ambulatory care or general practitioners’ 
offices, where access to more reliable information could 
be readily available.
STUDENT IMPACT
On a more personal note, I [Brian] joined this service- 
learning project while on my experiential training 
experience as a student who was beginning his journey 
into clinical practice. Being able to start my rotations 
with such a unique practice site and project helped 
prepare me for the rest of my clinical requirements. As 
a new rotation student, the opportunity to educate and 
interact with such a diverse patient population was a 
terrific experience for me to have right out of the gate. 
Being able to personally educate 63 patients in a mat-
ter of a few days allowed me to gain a confidence in 
interacting with patients that I was able to carry with 
me through the rest of my experiential training. Aside 
from gaining in my own clinical competency regard-
ing patient counseling, I was also able to contribute as 
nearly 1,300 community members received personal edu-
cation about a disease state that is predicted to become 
more common and has the potential to cause significant 
morbidity and mortality issues for affected patients. In 
addition to the 1,288 citizens who received this individual 
education, many more family members and caretakers, 
who were present with their loved ones at the time of 
counseling but deferred to take part in the study, learned 
about AF and will be able to share what they learned 
with others they care about. This is especially important 
considering that the United Kingdom has the highest 
rate of death attributed to AF globally, with nearly 1 in 
100 deaths being attributed to the disease. Directly, 37 
patients were identified as being potentially in AF, 18 of 
whom were previously unaware and not receiving appro-
priate medical care guided at minimizing the potential 
risks of AF such as stroke and other cardiovascular dis-
orders. More importantly than identifying these patients 
was the immediate connection to further care that was 
offered to ensure proper risk reduction strategies could be 
implemented in this patient group.
While the patients identified as potentially being in a 
state of arrhythmia likely received the most benefit from 
this service- learning project, the remaining patients in 
the “Normal” Kardia screening group also benefitted 
greatly. Aside from the verbal education, this group had 
the opportunity to see their ECG being taken in real 
time, which was a very exciting and interesting experi-
ence for many of these patients. This unique screening 
tool is what initially piqued many patients’ interest, and 
that initial interest is what opened the door to many of 
the great discussions and questions that took place. The 
Kardia’s ability to display the patient’s heart rhythm 
for them to see was a new and very unique experience 
for many of the participants. Being able to follow the 
rhythm and beat of their heart on the spot was a great 
way for patients to make the connection between the 
education we provided and themselves, making our 
efforts much more relevant for many of them. The enjoy-
ment expressed by the patients also lends to the idea of 
them being more willing to participate in similar public 
health initiatives in the future.
While this service- learning project was largely success-
ful and benefitted numerous people, there were some 
barriers that could be better anticipated for similar 
service- learning events in the future. One improve-
ment to be made for future screening efforts would be 
to better track patient outcomes after they were identi-
fied as potentially arrhythmic and referred on to further 
care. While the AliveCor Kardia screening system is 
considered to be quite accurate, being able to confirm 
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a core member of an interprofessional team as I col-
laborated closely with preregistration pharmacists and 
specialized cardiac nurses throughout the project. Being 
able to work with other health care team members is a 
vital skill to have in any capacity as a pharmacist, and 
this experience will help me acclimate to other health 
care teams as I continue to advance in my career and 
ensure patients receive the best outcomes possible as I 
practice in the future.
CONCLUSION
In summary, this service- learning project was mutually 
beneficial to both the community and myself [Brian] to 
a further extent than I would have ever imagined when I 
was first introduced to the project. I was able to experi-
ence an entirely new health care system firsthand, meet 
and educate patients that were genuinely interested 
in our project, and learn from fellow health care team 
members at the top of their fields, all while providing 
valuable education to members of the community. The 
authors hope that this article helps to raise awareness 
regarding atrial fibrillation and its associated morbid-
ity and mortality, while also providing ideas for others 
to help educate and provide for patients in their own 
communities.
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